Curvebeam AI Ltd. ( (AU:CVB) ) just unveiled an announcement.
CurveBeam AI Limited announced that it does not anticipate any significant adverse effects from the recent US tariffs, as most of its manufacturing is conducted in the United States with components sourced domestically. The company has a robust inventory strategy to mitigate supply chain disruptions and will continue to monitor the tariff situation closely. This proactive approach is expected to maintain its operational stability and industry positioning.
More about Curvebeam AI Ltd.
CurveBeam AI Limited is a company that develops, manufactures, and sells specialized medical imaging (CT) scanners, along with AI SaaS-based clinical assessment solutions. These products are designed to assist medical practitioners in managing musculoskeletal conditions. Their flagship product, the HiRise™ CT scanner, offers both weight-bearing and non-weight-bearing CT scans, providing advantages over traditional CT or MRI devices. The company operates from its corporate office in Melbourne, Australia, and has its global operations headquarters in Hatfield, Pennsylvania, USA.
YTD Price Performance: -25.00%
Average Trading Volume: 319,429
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$40.97M
See more insights into CVB stock on TipRanks’ Stock Analysis page.